Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly missed statistical significance. She shares her take on the totality of the data and discusses the road ahead, including a Q3 meeting the company will have with FDA.
View all episodes
By BiotechTV
5
22 ratings
Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly missed statistical significance. She shares her take on the totality of the data and discusses the road ahead, including a Q3 meeting the company will have with FDA.
4,235 Listeners
30,752 Listeners
43,883 Listeners
4,205 Listeners
2,304 Listeners
323 Listeners
5,941 Listeners
32 Listeners
431 Listeners
29,276 Listeners
343 Listeners
17 Listeners
5 Listeners
4 Listeners
0 Listeners
2 Listeners